Prolia

Type: Product
Name: Prolia
First reported Sep 19 2014 - Updated Sep 19 2014 - 2 reports

Denosumab After Teriparatide Boosts Bone-Density Gains

HOUSTON — High-risk osteoporosis patients who are transitioned to the antiresorptive drug denosumab ( Prolia, Amgen) following a previous regimen that includes teriparatide ( Forteo, Eli Lilly ) show the most favorable outcomes, compared with other ... [Published American Journal of Public Health - Sep 19 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 3 reports

Amgen Posts Results from Exploratory Analyses Evaluating Long-Term Impact of Treatment with Prolia (Denosumab) in Postmenopausal Women with Osteoporosis

According to a release from the Company, Prolia is the first approved therapy that specifically targets RANK Ligand, an essential regulator of bone-removing cells (osteoclasts). Data were presented at the American Society for Bone and Mineral Research ... [Published Individual.com - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Amgen, Inc. Poised To Break Higher

After hitting more highs over the past month, the last week or two has been somewhat of a choppy period of time in the stock market.The end of last week and start to this week drew a lot of stocks lower, and as has commonly been the case this year, biotech ... [Published Benzinga.com - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Amgen announces encouraging results from Phase III fracture analysis

From January to March 2012, this study examined 6,187 women at or over age 50 at high risk for fracture in the MarketScan Commercial and Medicare databases who newly initiated treatment with Prolia or other osteoporosis therapies (teriparatide, raloxifene, ... [Published Individual.com - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Merck osteoporosis drug does not wow

Share this article:Merck's odanacatib is not projected to be a big earnerMerck's Phase-III osteoporosis medication odanacatib showed that the weekly cathepsin K inhibitor significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures ... [Published Medical Marketing And Media - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 16 2014 - 2 reports

Amgen research shows long-term benefits of Prolia

:05 in Pharmaceutical Company Product News Amgen has announced new clinical trial data that underlines the long-term benefits its drug Prolia can bring for postmenopausal osteoporosis patients. A new exploratory analysis of the open-label extension study ... [Published Zenopa - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density

THOUSAND OAKS, Calif."Fractures or broken bones due to osteoporosis are very common and often have a life altering impact on an older woman and her family," said Michael McClungResults from one analysis showed that treatment with romosozumab led to significant ... [Published Bio-Medicine - Sep 15 2014]
Entities: Phase II, Density, Mineral
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Liraglutide, aiming for new indication, gets new name

Share this article:Liraglutide is known to diabetics by the name Victoza.An FDA advisory panel said Thursday that the regulator should greenlight an obesity indication for Novo Nordisk's GLP-1 liraglutide, with a vote of 14-1 in favor.Although known to ... [Published Medical Marketing And Media - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 2 reports

Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting

THOUSAND OAKS, Calif.Prolia data consist of 18 abstracts, including several exploratory analyses evaluating eight years of Prolia therapy from the open-label extension study of the pivotal Phase 3 fracture trial. Analyses report the percentage of women ... [Published Bio-Medicine - Sep 10 2014]
Entities: Prolia, Amgen Inc, Mineral
First reported Sep 04 2014 - Updated Sep 05 2014 - 1 reports

More Evidence Ties Some Bone-Building Drugs to Rare Fractures

THURSDAY, Sept. 4, 2014 (HealthDay News) -- Taking osteoporosis drugs called bisphosphonates to help prevent fractures may carry a slight risk for unusual breaks in the thigh bone, Swedish researchers report.For those who took bisphosphonates for four ... [Published Health Finder - Sep 04 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Fracture risk drug now for men

Denosumab, a monoclonal antibody that reduces bone resorption, is now licensed for the treatment of osteoporosis in men who are at increased risk of fractures. Under the brand name Prolia, denosumab was formerly restricted to women as a treatment for ... [Published Trends In Urology & Men's health - Sep 01 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Pain after 6 years on different medication

First time posting and hopping for help. I have been diagnosed with osteoporosis 6 years ago during a x-Ray for pneumonia at the age of 42. I'm not sure of my scores because I haven't had a bone scan in a year in a half. I was showing some improvement ... [Published HealthBoards - Aug 19 2014]

Quotes

"We found that teriparatide does not adequately prevent bone loss after denosumab, whereas denosumab stabilizes or increases bone-mineral density [BMD]"
"This combination seems to be a very effective option for the future treatment of osteoporosis."
...which can have significant impact on a patient's life," said Sean E Harper, M D , executive vice president of Research and Development at Amgen. "We are pleased to present these new Prolia analyses at this year's meeting, which add to the growing body of evidence supporting proven treatments for osteoporosis."
...are needed to help manage the continuum of the disease," said Sean E Harper , M D , executive vice president of Research and Development at Amgen. "Limited data exists on the risks and benefits of the long-term treatment of osteoporosis, and we're excited to help address this gap with the large body of Prolia data we will present at this year's meeting."

More Content

All (33) | News (28) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Denosumab After Teriparatide Boosts Bone-Densit... [Published American Journal of Public Health - Sep 19 2014]
Romosozumab Benefits Sustained After Transition... [Published General Medicine eJournal - Sep 19 2014]
Amgen Posts Results from Exploratory Analyses E... [Published Individual.com - Sep 18 2014]
UCB-Amgen Reveals Positive Data on Romosozumab ... [Published Zacks.com - Sep 17 2014]
Amgen Announces 23 Abstracts To Be Presented At... [Published 4 Traders - Sep 17 2014]
Amgen, Inc. Poised To Break Higher [Published Benzinga.com - Sep 17 2014]
Amgen announces encouraging results from Phase ... [Published Individual.com - Sep 17 2014]
Merck osteoporosis drug does not wow [Published Medical Marketing And Media - Sep 17 2014]
Amgen research shows long-term benefits of Prolia [Published Zenopa - Sep 16 2014]
FDA Approves Baxter's RIXUBIS; TG Therapeutics ... [Published BioMedReports - Sep 16 2014]
Amgen: Phase 2 Study Of Romosozumab Shows Incre... [Published RTTNews.com - Sep 15 2014]
New Analyses Of Phase 2 Study Presented At ASBM... [Published Bio-Medicine - Sep 15 2014]
Amgen Announces Results From Several New Explor... [Published PR Newswire: General Business - Sep 15 2014]
Liraglutide, aiming for new indication, gets ne... [Published Medical Marketing And Media - Sep 12 2014]
Amgen Announces 23 Abstracts To Be Presented At... [Published Bio-Medicine - Sep 10 2014]
Amgen Announces 23 Abstracts To Be Presented At... [Published PR Newswire: General Business - Sep 10 2014]
Osteoporosis Drugs Work, But Review Finds No Cl... [Published US News & World Report - Sep 08 2014]
More Evidence Ties Some Bone-Building Drugs to ... [Published Health Finder - Sep 04 2014]
Fracture risk drug now for men [Published Trends In Urology & Men's health - Sep 01 2014]
Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen... [Published Jutia Group - Aug 28 2014]
Why Amgen Stock Is A Long-Term Investment Oppor... [Published Seeking Alpha - Aug 27 2014]
Microgravity Research Breaks Down How to Build ... [Published MoneyShow.com - Aug 25 2014]
Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly ... [Published Jutia Group - Aug 21 2014]
Pain after 6 years on different medication [Published HealthBoards - Aug 19 2014]
Osteoporosis drugs destroy bones they are 'alle... [Published Examiner.com - Aug 18 2014]
Prolia And Femur Fractures: Three Recent Case R... [Published Drug Injury Watch - Aug 12 2014]
Half Yearly Report [Published TrustNet - Jul 23 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 11 2014]
1st Quarter Results [Published TrustNet - Apr 30 2014]
Amgen's net earnings dips by 25% to $1,073 mill... [Published PharmaBiz - Apr 23 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Amgen Announces Results From Several New Explor... [Published PR Newswire: General Business - Sep 15 2014]
THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia® (denosumab) ...
Amgen Announces 23 Abstracts To Be Presented At... [Published PR Newswire: General Business - Sep 10 2014]
THOUSAND OAKS, Calif., Sept. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present data from multiple Prolia® (denosumab) and romosozumab study analyses at the American Society for Bone and Mineral Research (ASBMR) 2014 ...
Pain after 6 years on different medication [Published HealthBoards - Aug 19 2014]
First time posting and hopping for help. I have been diagnosed with osteoporosis 6 years ago during a x-Ray for pneumonia at the age of 42. I'm not sure of my scores because I haven't had a bone scan in a year in a half. I was showing some improvement ...
Prolia And Femur Fractures: Three Recent Case R... [Published Drug Injury Watch - Aug 12 2014]
While Prolia Is An Alternative To Bisphosphonates Such As Fosamax, It Has Similar Increased Risk Of Low-Stress Femur Fractures Side Effect (Posted by Tom Lamb at DrugInjuryWatch.com ) The association between stress fractures of the femur, or ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 11 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.